In search of antiepileptogenic treatments for post-traumatic epilepsy

Patricia G. Saletti, Idrish Ali, Pablo M. Casillas-Espinosa, Bridgette D. Semple, Christos Panagiotis Lisgaras, Solomon L. Moshé, Aristea S. Galanopoulou

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Post-traumatic epilepsy (PTE) is diagnosed in 20% of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.

Original languageEnglish
Pages (from-to)86-99
Number of pages14
JournalNeurobiology of Disease
Volume123
DOIs
Publication statusPublished - Mar 2019

Keywords

  • Antiepileptogenesis
  • Disease modification
  • Inflammation
  • Iron
  • Neurodegeneration
  • Outcomes
  • Preclinical trial
  • Tau
  • Traumatic brain injury

Cite this

Saletti, Patricia G. ; Ali, Idrish ; Casillas-Espinosa, Pablo M. ; Semple, Bridgette D. ; Lisgaras, Christos Panagiotis ; Moshé, Solomon L. ; Galanopoulou, Aristea S. / In search of antiepileptogenic treatments for post-traumatic epilepsy. In: Neurobiology of Disease. 2019 ; Vol. 123. pp. 86-99.
@article{b5dc4ba0dc914f47878265d6e51924ca,
title = "In search of antiepileptogenic treatments for post-traumatic epilepsy",
abstract = "Post-traumatic epilepsy (PTE) is diagnosed in 20{\%} of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.",
keywords = "Antiepileptogenesis, Disease modification, Inflammation, Iron, Neurodegeneration, Outcomes, Preclinical trial, Tau, Traumatic brain injury",
author = "Saletti, {Patricia G.} and Idrish Ali and Casillas-Espinosa, {Pablo M.} and Semple, {Bridgette D.} and Lisgaras, {Christos Panagiotis} and Mosh{\'e}, {Solomon L.} and Galanopoulou, {Aristea S.}",
year = "2019",
month = "3",
doi = "10.1016/j.nbd.2018.06.017",
language = "English",
volume = "123",
pages = "86--99",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Elsevier",

}

In search of antiepileptogenic treatments for post-traumatic epilepsy. / Saletti, Patricia G.; Ali, Idrish; Casillas-Espinosa, Pablo M.; Semple, Bridgette D.; Lisgaras, Christos Panagiotis; Moshé, Solomon L.; Galanopoulou, Aristea S.

In: Neurobiology of Disease, Vol. 123, 03.2019, p. 86-99.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - In search of antiepileptogenic treatments for post-traumatic epilepsy

AU - Saletti, Patricia G.

AU - Ali, Idrish

AU - Casillas-Espinosa, Pablo M.

AU - Semple, Bridgette D.

AU - Lisgaras, Christos Panagiotis

AU - Moshé, Solomon L.

AU - Galanopoulou, Aristea S.

PY - 2019/3

Y1 - 2019/3

N2 - Post-traumatic epilepsy (PTE) is diagnosed in 20% of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.

AB - Post-traumatic epilepsy (PTE) is diagnosed in 20% of individuals with acquired epilepsy, and can impact significantly the quality of life due to the seizures and other functional or cognitive and behavioral outcomes of the traumatic brain injury (TBI) and PTE. There is no available antiepileptogenic or disease modifying treatment for PTE. Animal models of TBI and PTE have been developed, offering useful insights on the value of inflammatory, neurodegenerative pathways, hemorrhages and iron accumulation, calcium channels and other target pathways that could be used for treatment development. Most of the existing preclinical studies test efficacy towards pathologies of functional recovery after TBI, while a few studies are emerging testing the effects towards induced or spontaneous seizures. Here we review the existing preclinical trials testing new candidate treatments for TBI sequelae and PTE, and discuss future directions for efforts aiming at developing antiepileptogenic and disease-modifying treatments.

KW - Antiepileptogenesis

KW - Disease modification

KW - Inflammation

KW - Iron

KW - Neurodegeneration

KW - Outcomes

KW - Preclinical trial

KW - Tau

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=85049305403&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2018.06.017

DO - 10.1016/j.nbd.2018.06.017

M3 - Review Article

VL - 123

SP - 86

EP - 99

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -